ZLAB Zai Lab Limited

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naÃ¯ve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; TPX-0022, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin-17; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. It has development, license, and collaboration agreements with GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; SchrÃ¶dinger, Inc.; and argenx BV. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Recent Analyst Ratings for Zai Lab Limited

Date	Price Target	Rating	Analyst
3/7/2025	$55.00	Sector Outperform	Scotiabank
3/3/2025	$29.00 → $36.10	Buy → Neutral	BofA Securities
12/14/2023	$47.50	Overweight	Morgan Stanley
8/10/2023	$70.00	Overweight	Cantor Fitzgerald
3/2/2022	$194.00 → $102.00	Outperform	SVB Leerink
1/21/2022	$64.00	Outperform	Macquarie
12/15/2021	$189.00 → $136.00	Overweight	JP Morgan
11/11/2021	$222.00 → $217.00	Buy	Citigroup
11/10/2021	$200.00 → $194.00	Outperform	SVB Leerink
10/12/2021		Market Perform	Bernstein

See more ratings

Zai Lab Limited

Peers

Recent Analyst Ratings for Zai Lab Limited

Zai Lab Limited Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Chen Yajing sold $288,540 worth of American Depositary Shares (9,618 units at $30.00), decreasing direct ownership by 36% to 17,429 units (SEC Form 4)

Chairperson & CEO Du Ying exercised 96,389 units of American Depositary Shares at a strike of $0.60 and sold $2,731,507 worth of American Depositary Shares (96,389 units at $28.34) (SEC Form 4)

Director Morrison Scott W sold $715,086 worth of American Depositary Shares (23,799 units at $30.05), decreasing direct ownership by 50% to 23,702 units (SEC Form 4)

Chairperson & CEO Du Ying exercised 100,000 units of American Depositary Shares at a strike of $0.60 and sold $2,953,308 worth of American Depositary Shares (100,000 units at $29.53) (SEC Form 4)

Officer Smiley Joshua L converted options into 7,145 units of American Depositary Shares and sold $111,044 worth of American Depositary Shares (3,354 units at $33.11), increasing direct ownership by 6% to 67,345 units (SEC Form 4)

Chief Legal Officer Edmondson Frazor Titus Iii converted options into 5,032 units of American Depositary Shares and sold $62,044 worth of American Depositary Shares (1,874 units at $33.11), increasing direct ownership by 12% to 30,375 units (SEC Form 4)

Chairperson & CEO Du Ying converted options into 6,750 units of American Depositary Shares and sold $97,503 worth of American Depositary Shares (2,945 units at $33.11), increasing direct ownership by 0.80% to 479,851 units (SEC Form 4)

Chief Financial Officer Chen Yajing converted options into 2,500 units of American Depositary Shares and sold $30,592 worth of American Depositary Shares (924 units at $33.11), increasing direct ownership by 6% to 27,047 units (SEC Form 4)

Officer Amado Rafael sold $100,284 worth of American Depositary Shares (3,029 units at $33.11) and converted options into 5,391 units of American Depositary Shares, increasing direct ownership by 6% to 45,178 units (SEC Form 4)

Chief Legal Officer Edmondson Frazor Titus Iii converted options into 17,258 units of American Depositary Shares and sold $156,821 worth of American Depositary Shares (4,369 units at $35.89), increasing direct ownership by 90% to 27,217 units (SEC Form 4)

Zai Lab Limited Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Scotiabank initiated coverage on Zai Lab with a new price target

Zai Lab downgraded by BofA Securities with a new price target

Morgan Stanley initiated coverage on Zai Lab with a new price target

Cantor Fitzgerald initiated coverage on Zai Lab with a new price target

SVB Leerink reiterated coverage on Zai Lab with a new price target

Macquarie initiated coverage on Zai Lab with a new price target

JP Morgan reiterated coverage on Zai Lab with a new price target

Citigroup reiterated coverage on Zai Lab with a new price target

SVB Leerink reiterated coverage on Zai Lab with a new price target

Bernstein initiated coverage on Zai Lab

Zai Lab Limited SEC Filings

SEC Form 144 filed by Zai Lab Limited

Zai Lab Limited filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

SEC Form 144 filed by Zai Lab Limited

SEC Form 10-Q filed by Zai Lab Limited

Zai Lab Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEFA14A filed by Zai Lab Limited

SEC Form DEF 14A filed by Zai Lab Limited

SEC Form PRE 14A filed by Zai Lab Limited

Zai Lab Limited Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

Smiley Joshua L bought $119,600 worth of American Depositary Shares (4,000 units at $29.90), increasing direct ownership by 24% to 20,527 units (SEC Form 4)

Smiley Joshua L bought $134,650 worth of American Depositary Shares (5,000 units at $26.93), increasing direct ownership by 43% to 16,527 units (SEC Form 4)

Zai Lab Limited Leadership Updates

Live Leadership Updates

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

Zai Lab Appoints Michel Vounatsos To Its Board of Directors

Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer

Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer

Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors

Zai Lab Appoints Scott Morrison to its Board of Directors